Chronic Inflammation Index-Based Tumor Subsite Classification Correlated with Chemotherapy Benefit and Survival Outcomes in Stage II-III Colorectal Cancer
Ying Lu,1,* Qiu-Ying Ye,1– 3,* Ou Mei,4,* Ya-Nan Li,1 Yue Peng,1 Hou-Qun Ying,1,3,5 Xue-Xin Cheng1 1Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China; 2Depa...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-05-01
|
| Series: | Journal of Inflammation Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/chronic-inflammation-index-based-tumor-subsite-classification-correlat-peer-reviewed-fulltext-article-JIR |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849417908188348416 |
|---|---|
| author | Lu Y Ye QY Mei O Li YN Peng Y Ying HQ Cheng XX |
| author_facet | Lu Y Ye QY Mei O Li YN Peng Y Ying HQ Cheng XX |
| author_sort | Lu Y |
| collection | DOAJ |
| description | Ying Lu,1,&ast; Qiu-Ying Ye,1– 3,&ast; Ou Mei,4,&ast; Ya-Nan Li,1 Yue Peng,1 Hou-Qun Ying,1,3,5 Xue-Xin Cheng1 1Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China; 2Department of Medical Technology, Jiangxi Medical College, Shangrao, 334000, People’s Republic of China; 3Department of Laboratory Medicine, Central Hospital of Shangrao City, Shangrao, 334000, People’s Republic of China; 4Department of Orthopedics, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, People’s Republic of China; 5Shangrao Medical Center, The Second Affiliated Hospital of Nanchang University, Shangrao, 334000, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Xue-Xin Cheng, Department of Clinical Laboratory, Immunity and Inflammation Key Laboratory of Jiangxi Province, The Second Affiliated Hospital of Nanchang University, No. 1 of Minde Road, Nanchang, 330006, People’s Republic of China, Tel/Fax +86 0791-86297662, Email cxxncu@163.com Hou-Qun Ying, Department of Clinical Laboratory, Immunity and Inflammation Key Laboratory of Jiangxi Province, The Second Affiliated Hospital of Nanchang University, No. 1 of Minde Road, Nanchang, 330006, People’s Republic of China, Tel/Fax +86 0791-86297662, Email yinghouqun2013@163.comPurpose: This study aimed to develop and validate an integrated inflammatory prognostic index and to investigate associations between primary tumor location, chronic inflammatory status, adjuvant chemotherapy response, and survival outcomes in stage II–III colorectal cancer (CRC).Patients and Methods: A total of 1413 stage II–III CRC patients who underwent radical resection were enrolled and divided into discovery and validation cohorts. Preoperative systemic inflammatory biomarkers were quantified, and patients were followed for 3 years to establish an optimal chronic inflammatory index (CII) and evaluate its association with survival and chemotherapy efficacy across primary tumor locations.Results: The comprehensive CII was the top-performing prognostic biomarker, with time-dependent AUCs of 0.71(95% CI: 0.68– 0.74) for 36-month RFS and 0.74(95% CI: 0.70– 0.77) for OS. Furthermore, the 3C (CII, CEA and CA19-9) combined score demonstrated prognostic predictive AUCs of 0.74(95% CI: 0.71– 0.77) for RFS and 0.76(95% CI: 0.72– 0.79) for OS in the overall population. The splenic flexure and ascending colon showed significantly elevated CII levels versus other subsites, and the disease was divided into the proximal colon, transverse colon, distal colon and rectum. A significant CII gradient emerged across subsites (proximal > transverse > distal > rectal), with corresponding survival decrements (log-rank p < 0.001). Proximal CRC exhibited marked worse survival outcomes (p = 0.002 for RFS and p = 0.001 for OS) and inferior chemotherapy efficacy (p < 0.001 for RFS and OS) versus rectal cancer, with no significant differences between adjacent subsites (all p > 0.05).Conclusion: The validated CII represents a biologically relevant, subsite-specific prognostic biomarker in CRC. The chronic inflammation-based tumor subsite classification correlated with chemotherapy efficacy and clinical outcomes, highlighting its potential for personalized treatment strategies.Keywords: colorectal cancer, systemic inflammation, location-based therapy, precision medicine |
| format | Article |
| id | doaj-art-4dd82b3a68064aea89e8ccbce9746158 |
| institution | Kabale University |
| issn | 1178-7031 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Inflammation Research |
| spelling | doaj-art-4dd82b3a68064aea89e8ccbce97461582025-08-20T03:32:36ZengDove Medical PressJournal of Inflammation Research1178-70312025-05-01Volume 18Issue 167676781103304Chronic Inflammation Index-Based Tumor Subsite Classification Correlated with Chemotherapy Benefit and Survival Outcomes in Stage II-III Colorectal CancerLu Y0Ye QY1Mei O2Li YN3Peng Y4Ying HQ5Cheng XX6Department of Clinical LaboratoryDepartment of Clinical LaboratoryDepartment of OrthopedicsDepartment of Clinical LaboratoryDepartment of Clinical LaboratoryDepartment of Clinical LaboratoryDepartment of Clinical LaboratoryYing Lu,1,&ast; Qiu-Ying Ye,1– 3,&ast; Ou Mei,4,&ast; Ya-Nan Li,1 Yue Peng,1 Hou-Qun Ying,1,3,5 Xue-Xin Cheng1 1Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China; 2Department of Medical Technology, Jiangxi Medical College, Shangrao, 334000, People’s Republic of China; 3Department of Laboratory Medicine, Central Hospital of Shangrao City, Shangrao, 334000, People’s Republic of China; 4Department of Orthopedics, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, People’s Republic of China; 5Shangrao Medical Center, The Second Affiliated Hospital of Nanchang University, Shangrao, 334000, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Xue-Xin Cheng, Department of Clinical Laboratory, Immunity and Inflammation Key Laboratory of Jiangxi Province, The Second Affiliated Hospital of Nanchang University, No. 1 of Minde Road, Nanchang, 330006, People’s Republic of China, Tel/Fax +86 0791-86297662, Email cxxncu@163.com Hou-Qun Ying, Department of Clinical Laboratory, Immunity and Inflammation Key Laboratory of Jiangxi Province, The Second Affiliated Hospital of Nanchang University, No. 1 of Minde Road, Nanchang, 330006, People’s Republic of China, Tel/Fax +86 0791-86297662, Email yinghouqun2013@163.comPurpose: This study aimed to develop and validate an integrated inflammatory prognostic index and to investigate associations between primary tumor location, chronic inflammatory status, adjuvant chemotherapy response, and survival outcomes in stage II–III colorectal cancer (CRC).Patients and Methods: A total of 1413 stage II–III CRC patients who underwent radical resection were enrolled and divided into discovery and validation cohorts. Preoperative systemic inflammatory biomarkers were quantified, and patients were followed for 3 years to establish an optimal chronic inflammatory index (CII) and evaluate its association with survival and chemotherapy efficacy across primary tumor locations.Results: The comprehensive CII was the top-performing prognostic biomarker, with time-dependent AUCs of 0.71(95% CI: 0.68– 0.74) for 36-month RFS and 0.74(95% CI: 0.70– 0.77) for OS. Furthermore, the 3C (CII, CEA and CA19-9) combined score demonstrated prognostic predictive AUCs of 0.74(95% CI: 0.71– 0.77) for RFS and 0.76(95% CI: 0.72– 0.79) for OS in the overall population. The splenic flexure and ascending colon showed significantly elevated CII levels versus other subsites, and the disease was divided into the proximal colon, transverse colon, distal colon and rectum. A significant CII gradient emerged across subsites (proximal > transverse > distal > rectal), with corresponding survival decrements (log-rank p < 0.001). Proximal CRC exhibited marked worse survival outcomes (p = 0.002 for RFS and p = 0.001 for OS) and inferior chemotherapy efficacy (p < 0.001 for RFS and OS) versus rectal cancer, with no significant differences between adjacent subsites (all p > 0.05).Conclusion: The validated CII represents a biologically relevant, subsite-specific prognostic biomarker in CRC. The chronic inflammation-based tumor subsite classification correlated with chemotherapy efficacy and clinical outcomes, highlighting its potential for personalized treatment strategies.Keywords: colorectal cancer, systemic inflammation, location-based therapy, precision medicinehttps://www.dovepress.com/chronic-inflammation-index-based-tumor-subsite-classification-correlat-peer-reviewed-fulltext-article-JIRColorectal cancersystemic inflammationlocation-based therapyprecision medicine |
| spellingShingle | Lu Y Ye QY Mei O Li YN Peng Y Ying HQ Cheng XX Chronic Inflammation Index-Based Tumor Subsite Classification Correlated with Chemotherapy Benefit and Survival Outcomes in Stage II-III Colorectal Cancer Journal of Inflammation Research Colorectal cancer systemic inflammation location-based therapy precision medicine |
| title | Chronic Inflammation Index-Based Tumor Subsite Classification Correlated with Chemotherapy Benefit and Survival Outcomes in Stage II-III Colorectal Cancer |
| title_full | Chronic Inflammation Index-Based Tumor Subsite Classification Correlated with Chemotherapy Benefit and Survival Outcomes in Stage II-III Colorectal Cancer |
| title_fullStr | Chronic Inflammation Index-Based Tumor Subsite Classification Correlated with Chemotherapy Benefit and Survival Outcomes in Stage II-III Colorectal Cancer |
| title_full_unstemmed | Chronic Inflammation Index-Based Tumor Subsite Classification Correlated with Chemotherapy Benefit and Survival Outcomes in Stage II-III Colorectal Cancer |
| title_short | Chronic Inflammation Index-Based Tumor Subsite Classification Correlated with Chemotherapy Benefit and Survival Outcomes in Stage II-III Colorectal Cancer |
| title_sort | chronic inflammation index based tumor subsite classification correlated with chemotherapy benefit and survival outcomes in stage ii iii colorectal cancer |
| topic | Colorectal cancer systemic inflammation location-based therapy precision medicine |
| url | https://www.dovepress.com/chronic-inflammation-index-based-tumor-subsite-classification-correlat-peer-reviewed-fulltext-article-JIR |
| work_keys_str_mv | AT luy chronicinflammationindexbasedtumorsubsiteclassificationcorrelatedwithchemotherapybenefitandsurvivaloutcomesinstageiiiiicolorectalcancer AT yeqy chronicinflammationindexbasedtumorsubsiteclassificationcorrelatedwithchemotherapybenefitandsurvivaloutcomesinstageiiiiicolorectalcancer AT meio chronicinflammationindexbasedtumorsubsiteclassificationcorrelatedwithchemotherapybenefitandsurvivaloutcomesinstageiiiiicolorectalcancer AT liyn chronicinflammationindexbasedtumorsubsiteclassificationcorrelatedwithchemotherapybenefitandsurvivaloutcomesinstageiiiiicolorectalcancer AT pengy chronicinflammationindexbasedtumorsubsiteclassificationcorrelatedwithchemotherapybenefitandsurvivaloutcomesinstageiiiiicolorectalcancer AT yinghq chronicinflammationindexbasedtumorsubsiteclassificationcorrelatedwithchemotherapybenefitandsurvivaloutcomesinstageiiiiicolorectalcancer AT chengxx chronicinflammationindexbasedtumorsubsiteclassificationcorrelatedwithchemotherapybenefitandsurvivaloutcomesinstageiiiiicolorectalcancer |